Progress in Personalizing Chemotherapy for Bladder Cancer

被引：25

作者：

Chang, James S. ^{[1
]}

Lara, Primo N., Jr. ^{[1
]}

Pan, Chong-Xian ^{[1
,2
,3
,4
]}

机构：

[1] Univ Calif Davis, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA

[2] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA

[3] VA Northern Calif Hlth Care Syst, Dept Med, Mather, CA 95655 USA

[4] Univ Calif Davis, Ctr Canc, UC Davis Urothelial Carcinoma Initiat, Sacramento, CA 95817 USA

来源：

ADVANCES IN UROLOGY | 2012年 / 2012卷

关键词：

D O I：

10.1155/2012/364919

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.

引用

页数：10

共 98 条

[1]

Neoadjuvant chemotherapy in invasive bladder cancer:: Update of a systematic review and meta-analysis of individual patient data [J].

Abol-Enein, H ;

Bassi, P ;

Boyer, M ;

Coppin, CML ;

Cortesi, E ;

Grossman, HB ;

Hall, RR ;

Horwich, A ;

Malmström, PU ;

Martinez-Piñeiro, JA ;

Sengelov, L ;

Sherif, A ;

Wallace, DMA ;

Bono, AV ;

Goebell, PJ ;

Groshen, S ;

Torti, FM ;

Clarke, NW ;

Roberts, JT ;

Sylvester, R ;

Parmar, MKB ;

Stewart, LA ;

Tierney, JF ;

Vale, CL .

EUROPEAN UROLOGY, 2005, 48 (02) :202-206

[2]

The Bcl-2 protein family: Arbiters of cell survival [J].

Adams, JM ;

Cory, S .

SCIENCE, 1998, 281 (5381) :1322-1326

[3]

[Anonymous], 1999, Lancet, V354, P533

[4]

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].

Bellmunt, J. ;

Paz-Ares, L. ;

Cuello, M. ;

Cecere, F. L. ;

Albiol, S. ;

Guillem, V. ;

Gallardo, E. ;

Carles, J. ;

Mendez, P. ;

de la Cruz, J. J. ;

Taron, M. ;

Rosell, R. ;

Baselga, J. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :522-528

[5]

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer [J].

Bepler, G ;

Sharma, S ;

Cantor, A ;

Gautam, A ;

Haura, E ;

Simon, G ;

Sharma, A ;

Sommers, E ;

Robinson, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1878-1885

[6]

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[7]

Bepler Gerold, 2008, Cancer Control, V15, P130

[8]

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer [J].

Bochner, Bernard H. ;

Dalbagni, Guido ;

Kattan, Michael W. ;

Fearn, Paul ;

Vora, Kinjal ;

Seo, Hee Song ;

Zoref, Lauren ;

Abol-Enein, Hassan ;

Ghoneim, Mohamed A. ;

Bochner, Bernard H. ;

Dalbagni, Guido ;

Scardino, Peter T. ;

Bajorin, Dean ;

Skinner, Donald G. ;

Stein, John P. ;

Miranda, Gus ;

Gschwend, Juergen E. ;

Volkmer, Bjoern G. ;

Hautmann, Richard E. ;

Chang, Sam ;

Cookson, Michael ;

Smith, Joseph A. ;

Thalman, George ;

Studer, Urs E. ;

Lee, Cheryl T. ;

Montie, James ;

Wood, David ;

Puigvert, Fundacio ;

Palou, Juan ;

Fradet, Yyes ;

LaCombe, Louis ;

Simard, Pierre ;

Schoenberg, Mark P. ;

Lerner, Seth ;

Vazina, Amnon ;

Bassi, PierFrancesco ;

Murai, Masaru ;

Kikuchi, Eiji .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3967-3972

[9]

p53-mediated activation of miRNA34 candidate tumor-suppressor genes [J].

Bommer, Guido T. ;

Gerin, Isabelle ;

Feng, Ying ;

Kaczorowski, Andrew J. ;

Kuick, Rork ;

Love, Robert E. ;

Zhai, Yali ;

Giordano, Thomas J. ;

Qin, Zhaohui S. ;

Moore, Bethany B. ;

MacDougald, Ormond A. ;

Cho, Kathleen R. ;

Fearon, Eric R. .

CURRENT BIOLOGY, 2007, 17 (15) :1298-1307

[10]

Bonetti A, 1996, CLIN CANCER RES, V2, P1829

← 1 2 3 4 5 6 7 8 9 10 →